Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press67110.17650/1994-4098-2019-15-4-50-57MAMMOLOGY. REVIEWSМАММОЛОГИЯ. ОБЗОРНЫЕ СТАТЬИGeneral recommendations for the management of breast cancer (St. Gallen Expert Consensus developed at the 16th th International Breast Cancer Conference)Общие рекомендации по лечению рака молочной железы (позиция Панели экспертов St. Gallen 16-й Международной конференции по терапии рака молочной железы)https://orcid.org/0000-0003-0077-9619SemiglazovV. F.СемиглазовВ. Ф.
Russian Federation

68 Leningradskaya St., Pesochnyy Settlement, Saint Petersburg 197758

197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68

https://orcid.org/0000-0002-0871-9453PaltuevR. M.ПалтуевР. М.
Russian Federation

68 Leningradskaya St., Pesochnyy Settlement, Saint Petersburg 197758

Руслан Маликович Палтуев

197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68

paltuev@mail.ruhttps://orcid.org/0000-0002-8825-5221SemiglazovV. V.СемиглазовВ. В.
Russian Federation

68 Leningradskaya St., Pesochnyy Settlement, Saint Petersburg 197758

197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68

N.N. Petrov National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава России12122019154505711032020110320202019https://ojrs.abvpress.ru/ojrs/article/view/671

This article summarizes the results of the 16th St. Gallen International Breast Cancer Conference (March 2019), which traditionally resulted in the development of a new guideline for local/regional and systemic treatment of breast cancer.

В статье представлен обзор результатов 16-й Международной конференции по терапии рака молочной железы, состоявшейся в марте 2019 г. и традиционно завершившейся принятием рекомендаций по местно-регионарному и системному лечению рака молочной железы.

breast cancerSt. Gallen Expert Panelsentinel lymph node biopsyductal carcinomalobular carcinomaрак молочной железыПанель экспертов St. Gallenбиопсия сигнального лимфатического узладуктальная карциномалобулярная карцинома1. Burstein H.J., Lacchetti C., Anderson H. et al. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol 2019:37(5):423—38. DOI: 10.1200/JCO.18.01160.Burstein H.J., Lacchetti C., Anderson H. et al. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol 2019:37(5):423—38. DOI: 10.1200/JCO.18.01160.2. Curigliano G., Burstein H.J., Winer E.P. et al. De-escalating and escalating treatments early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017:28:1700-12.Curigliano G., Burstein H.J., Winer E.P. et al. De-escalating and escalating treatments early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017:28:1700-12.3. Semiglazov V.F., Semiglazov V.V., Dashyan G.A. et al. Phase II randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor positive breast cancer. Cancer 2007;110(2):224-54.Semiglazov V.F., Semiglazov V.V., Dashyan G.A. et al. Phase II randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor positive breast cancer. Cancer 2007;110(2):224-54.4. Semiglazov V.F., Dashyan G.A., Semiglazov VV et al. Prognostic values of breast cancer subtypes: from phase 2 randomised trial of neoadjuvant therapy. Breast 2015;24:S92.Semiglazov V.F., Dashyan G.A., Semiglazov VV et al. Prognostic values of breast cancer subtypes: from phase 2 randomised trial of neoadjuvant therapy. Breast 2015;24:S92.5. Gnant M., Pfeiler G., Steger G.G. et al. Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20(3):339-51. DOI: 10.1016/S1470-2045(18)30862-3.Gnant M., Pfeiler G., Steger G.G. et al. Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20(3):339-51. DOI: 10.1016/S1470-2045(18)30862-3.6. Gnant M., Mlineritsch B., Stoeger H. et al. Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol 2015:26(2):313-20.Gnant M., Mlineritsch B., Stoeger H. et al. Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol 2015:26(2):313-20.7. Sparano J.A., Gray R.J., Makower D.F. et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 2018;12379(2):111—21.Sparano J.A., Gray R.J., Makower D.F. et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 2018;12379(2):111—21.8. Martin M., Holmes F.A., Ejlertsen B. et al. ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18(12): 1688—700. DOI: 10.1016/51470-2045(17)30717-9.Martin M., Holmes F.A., Ejlertsen B. et al. ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18(12): 1688—700. DOI: 10.1016/51470-2045(17)30717-9.9. Sikov W.M., Berry D.A., Perou C.M. et al. Impact of the addition of carboplatin and/ or bevacizumab to neoadjuvant once-per-week pacltaxel followed by dose-dense doxorubicin and cyclophosphamide pathologic complete response rates stage IlIl triple-negative breast cancer: CALGB 40603 (Alliance). Clin Oncol 2015:33(1):13—21. DOI: 10.1200/JCo.2014.57.0572.Sikov W.M., Berry D.A., Perou C.M. et al. Impact of the addition of carboplatin and/ or bevacizumab to neoadjuvant once-per-week pacltaxel followed by dose-dense doxorubicin and cyclophosphamide pathologic complete response rates stage IlIl triple-negative breast cancer: CALGB 40603 (Alliance). Clin Oncol 2015:33(1):13—21. DOI: 10.1200/JCo.2014.57.0572.10. Loibl S., Weber K.E., Timms K.M. et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann Oncol 2018,29(12):2341 —7. DOI: 10.1093/annonc/mdy460.Loibl S., Weber K.E., Timms K.M. et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann Oncol 2018,29(12):2341 —7. DOI: 10.1093/annonc/mdy460.11. Masuda N., Lee S.J., Ohtani S. et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med 2017,376(22):2147—59. DOI: 10.1056/NEJMoa1612645.Masuda N., Lee S.J., Ohtani S. et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med 2017,376(22):2147—59. DOI: 10.1056/NEJMoa1612645.12. Martin M., Barrios C.H., Torrecilla L. et al. Efficacy results form the CIBOMA 2004-01/GEICAM 2003-11 study: a randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer. SABCS 2018.Martin M., Barrios C.H., Torrecilla L. et al. Efficacy results form the CIBOMA 2004-01/GEICAM 2003-11 study: a randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer. SABCS 2018.13. Von Minckwitz G., Procter M., de Azambuja E. et al. APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med 2017;377(2):122—31. DOI: 10.1056/NEJMoa1703643.Von Minckwitz G., Procter M., de Azambuja E. et al. APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med 2017;377(2):122—31. DOI: 10.1056/NEJMoa1703643.14. Gianni L., Pienkowski T., Im Y.H. et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab inpatients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): A multicentre, open-label, phase 2 randomised trial. Lancet Oncol 2016:17(6):791—800. DOI: 10.1016/S1470-2045(16)00163-7.Gianni L., Pienkowski T., Im Y.H. et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab inpatients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): A multicentre, open-label, phase 2 randomised trial. Lancet Oncol 2016:17(6):791—800. DOI: 10.1016/S1470-2045(16)00163-7.15. Schneeweiss A., Chia S., Hickish T. et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013:24(9):2278—84. DOI: 10.1093/annonc/mdt182.Schneeweiss A., Chia S., Hickish T. et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013:24(9):2278—84. DOI: 10.1093/annonc/mdt182.16. Earl H.M. PERSEPHONE: 6 versus (m) adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 noninferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. J Clin Oncol 2018;(15 Suppl):506. DOI: 10.1200/JCO.2018.36.15_suppl.506.Earl H.M. PERSEPHONE: 6 versus (m) adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 noninferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. J Clin Oncol 2018;(15 Suppl):506. DOI: 10.1200/JCO.2018.36.15_suppl.506.17. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 2018:19:27—39.Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 2018:19:27—39.